Published in Auto Immun Highlights on January 22, 2014
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (UNCOVER-3) | NCT01646177
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1) | NCT01695239
Therapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation. Int J Mol Sci (2016) 0.78
Th17 Pathway As a Target for Multipotent Stromal Cell Therapy in Dogs: Implications for Translational Research. PLoS One (2016) 0.76
Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatol Ther (2016) 0.76
Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J Gastroenterol (2016) 0.75
Overexpression and potential roles of NRIP1 in psoriasis. Oncotarget (2016) 0.75
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 27.49
Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 25.91
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Interleukin-17 family members and inflammation. Immunity (2004) 16.16
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem (2002) 14.34
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med (2006) 13.74
T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity (2007) 13.29
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest (2006) 11.89
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer (1983) 11.19
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet (2006) 9.56
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Risk of myocardial infarction in patients with psoriasis. JAMA (2006) 9.42
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet (2007) 8.07
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Rheumatoid arthritis association at 6q23. Nat Genet (2007) 6.71
Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet (2008) 6.42
Structure and signalling in the IL-17 receptor family. Nat Rev Immunol (2009) 6.38
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science (2011) 6.19
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med (2012) 6.01
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev (2003) 5.57
Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet (2008) 4.96
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet (2005) 4.80
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature (2013) 4.74
Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis (2005) 4.67
IL-17: prototype member of an emerging cytokine family. J Leukoc Biol (2002) 4.39
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol (2008) 4.18
Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol (2006) 4.12
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med (2005) 4.04
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 3.93
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 3.38
REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet (2009) 3.36
Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol (2008) 3.19
Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest (2003) 3.14
Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol (2005) 3.04
LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum (2010) 2.99
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res (2006) 2.67
Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66
Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis (2005) 2.61
Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut (2009) 2.50
Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol (2009) 2.46
In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum (2012) 2.31
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol (2008) 2.20
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum (2011) 2.11
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet (2009) 1.97
IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol (2010) 1.83
Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis. PLoS Genet (2011) 1.77
Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol (2008) 1.72
Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol (2009) 1.72
IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther (2007) 1.40
Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis (2006) 1.39
Comorbidities in patients with psoriasis. Am J Med (2009) 1.34
Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther (2012) 1.33
Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum (2008) 1.28
Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol (2013) 1.22
Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22
Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol (2008) 1.18
IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem (2011) 1.17
The IL-17 family cytokines in immunity and disease. J Clin Immunol (2010) 1.16
Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol (2008) 1.16
Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol (2008) 1.08
Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol (2011) 1.05
Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. J Invest Dermatol (2011) 1.04
T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis (1998) 1.02
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol (2011) 1.00
Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol (2008) 0.98
Interplay between environmental factors, articular involvement, and HLA-B27 in patients with psoriatic arthritis. Ann Rheum Dis (1992) 0.92
The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis. Int J Rheumatol (2012) 0.92
Psoriasis vulgaris--a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol (2001) 0.91
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci (2011) 0.90
Atherosclerosis in psoriatic arthritis. Autoimmun Rev (2011) 0.87
A role for TGFbeta signaling in the pathogenesis of psoriasis. J Invest Dermatol (2009) 0.87
Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden Early Arthritis cohort. Ann Rheum Dis (2012) 0.83
Angiogenic and inflammatory properties of psoriatic arthritis. ISRN Dermatol (2013) 0.83
Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha. Int J Immunopathol Pharmacol (2006) 0.83
T-helper 17 cells: the driving force of psoriasis and psoriatic arthritis. Int J Rheum Dis (2012) 0.81
Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal (2013) 0.80
Peripheral spondyloarthritis and psoriatic arthritis; overlaps and distinctions: a report from the GRAPPA 2012 annual meeting. J Rheumatol (2013) 0.80
Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg (2010) 0.80
Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis (2013) 0.79
Briakinumab for the treatment of plaque psoriasis. BioDrugs (2012) 0.78
Synovial fluid fibroblasts and lymphocytes support the osteoclastogenesis in human psoriatic arthritis. Ann N Y Acad Sci (2007) 0.77